Remission of type 2 diabetes: A critical appraisal

Michele Ricci; Juan José Mancebo-Sevilla; Lidia Cobos Palacios; Jaime Sanz-Cánovas; Almudena López-Sampalo; Halbert Hernández-Negrin; Miguel Angel Pérez-Velasco; Luis M Pérez-Belmonte; Maria Rosa Bernal-López; Ricardo Gómez-Huelgas

doi:10.3389/fendo.2023.1125961

Remission of type 2 diabetes: A critical appraisal

Front Endocrinol (Lausanne). 2023 Apr 3:14:1125961. doi: 10.3389/fendo.2023.1125961. eCollection 2023.

Authors

Michele Ricci^{1

2}, Juan José Mancebo-Sevilla^{1

2}, Lidia Cobos Palacios^{1

2}, Jaime Sanz-Cánovas^{1

2}, Almudena López-Sampalo^{1

2}, Halbert Hernández-Negrin^{1

2}, Miguel Angel Pérez-Velasco¹, Luis M Pérez-Belmonte^{1

2

3}, Maria Rosa Bernal-López^{1

2

4}, Ricardo Gómez-Huelgas^{1

2

4}

Affiliations

¹ Internal Medicine Clinical Management Unit, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA-Plataforma BIONAND), Malaga, Spain.
² Faculty of Medicine, Universidad de Málaga, Malaga, Spain.
³ Servicio de Medicina Interna, Hospital Helicópteros Sanitarios, Marbella, Spain.
⁴ Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain.

No abstract available

Keywords: no insulin hypoglycemic drugs; prevention; remission; type 2 diabetes; weight loss.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Diabetes Mellitus, Type 2* / therapy
Humans
Hypoglycemic Agents
Insulin

Substances

Hypoglycemic Agents
Insulin

Grants and funding

This work was supported by grants from the Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo RegionalFEDER, grants PI18/00766 and “Centros de Investigación En Red” (CIBER, CB06/03/0018). This study has also been funded by Instituto de Salud Carlos II (ISCIII) through the project PI21/00465 and co-funded by the European Union. MR, MP-V, JS-C, LC-P, and AL-S were supported by “Rio Hortega” program (CM22/00155, CM22/00225, CM20/00212, CM20/00125 and, CM21/00110, respectively) and MB-L was supported by “Miguel Servet Type II” program (CPII/00014) from the ISCIIIMadrid (Spain), cofunded by the Fondo Europeo de Desarrollo Regional-FEDER. MB-L (“Nicolas Monardes” program, C1-0005-2020) was supported by Consejeria de Salud, Junta de Andalucía and HH-N (PREDOC00826) was supported by Consejería de Transformación Económica, Industria, Conocimiento y Universidades.